ArticleBioinformation2026
Completion total pancreatectomy (CTP) for isolated PDAC recurrence.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a poor prognosis and currently represents the fourth leading cause of cancer-related death. Outcomes of completion total pancreatectomy (CTP) for recurrent pancreatic ductal adenocarcinoma (PDAC) remain insufficiently defined. Therefore, it is of interest to evaluate perioperative safety and oncological outcomes in 84 patients undergoing CTP for isolated PDAC recurrence. Clinical variables including (R0) resection rate, operative parameters, morbidity, mortality and survival outcomes were analyzed. CTP achieved R0 resection in most cases with acceptable morbidity and mortality, while improved survival was associated with disease-free interval >24 months, CA 19-9 <37 U/mL and absence of lymph node metastasis. Thus, we show CTP as a viable salvage option providing meaningful long-term survival in selected patients with recurrent PDAC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.